Astrazeneca AB has synthesized fibroblast activation protein-α (FAPα) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH), among others.

Sitryx Therapeutics Ltd. has disclosed nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators reported to be useful for the treatment of inflammatory disorders.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche, Inc. have described fluorescent probes acting as monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for diagnostic imaging of MAGL.

Incyte Corp. has divulged cyclin-dependent kinase 12 (CDK12) inhibitors reported to be useful for the treatment of cancer.

Actelion Pharmaceuticals Ltd. has identified PDGFR inhibitors reported to be useful for the treatment of pulmonary arterial hypertension (PAH).

University of Ottawa has synthesized ferroptosis inhibitors reported to be useful for the treatment of cancer, diabetes, myocardial infarction, amyotrophic lateral sclerosis, sepsis, shock, transplant rejection and Alzheimer’s dementia.

Ensem Therapeutics Inc. has disclosed quinazoline derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Acadia Pharmaceuticals Inc. has described G protein-coupled receptor GPR88 agonists reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD), substance abuse and dependence, schizophrenia, Tourette syndrome, bipolar disorder, Huntington's disease, Alzheimer's disease and Parkinson's disease.

Insilico Medicine IP Ltd. has divulged cyclin-dependent kinase 8 (CDK8) and/or CDK19 dual inhibitors reported to be useful for the treatment of autoimmune diseases and cancer.

Medshine Discovery Inc. has identified EGFR (del19/Thr790Met/Cys797Ser triple mutant) inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).